Targeting cytokines: Production and characterization of anti-TNF-α scfvs by phage display technology

Current Pharmaceutical Design

Volumn 19, Issue 15, 2013, Pages 2839-2847

  Abdolalizadeh, Jalal ^a,b,c   Nouri, Mohammad ^b   Zolbanin, Jafar Majidi ^b   Barzegari, Abolfazl ^a   Baradaran, Behzad ^b   Barar, Jaleh ^a,d   Coukos, George ^d,e   Omidi, Yadollah ^a,d  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Cytokines; Human tnf ; Immunotherapy; Monoclonal antibody; Phage display

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TUMOR NECROSIS FACTOR ALPHA; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BIOPANNING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOBLAST; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY TECHNOLOGY; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TECHNOLOGY; WESTERN BLOTTING;

BACTERIOPHAGES; BLOTTING, WESTERN; CYTOKINES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; MICROSCOPY, FLUORESCENCE; SINGLE-CHAIN ANTIBODIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876729230     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319150019     Document Type: Article

References (60)

1. Chang H, Qin W, Li Y, et al. A novel human scFv fragment against TNF-alpha from de novo design method. Mol Immunol 2007; 44: 3789-3796.
2. Chen W, Zhang J, Zhang T, et al. Improved Isolation of AntirhTNF-α scFvs from Phage Display Library by Bioinformatics. Mol Biotech 2009; 43: 20-28.
3. Chen Y, Diener K, Patel IR, et al. Phage display of functional human TNF-alpha converting enzyme catalytic domain: a rapid method for the production of stabilized proteolytic proteins for assay development and high-throughput screening. J Biomol Screen 2002; 7: 433-440.
4. Tempest PR, Barbanti E, Bremner P, et al. A humanized anti-tumor necrosis factor-alpha monoclonal antibody that acts as a partial, competitive antagonist of the template antibody. Hybridoma 1994; 13: 183-190.
5. Charles KA, Kulbe H, Soper R, et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009; 119: 3011-3023.
6. Smyth MJ, Johnstone RW. Role of TNF in lymphocyte-mediated cytotoxicity. Microsc Res Tech 2000; 50: 196-208.
7. Ware CF. Network communications: lymphotoxins, LIGHT, and TNF. AnnuRev Immunol 2005; 23: 787-819.
8. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 2010; 49: 1215-1228.
9. Krueger G, Callis K. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol 2004; 140: 218-225.
10. Moreland LW, Curtis JR. Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. Semin Arthritis Rheum 2009; 39: 132-143.
11. Sasi SP, Yan X, Enderling H, et al. Breaking the 'harmony' of TNF-alpha signaling for cancer treatment. Oncogene 2012; 31: 4117-4127.
12. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL. Anti-TNF-alpha therapies: the next generation. Nat Rev Drug Discov 2003; 2: 736-746.
13. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10: 301-316.
14. Dommasch E, Gelfand JM. Is there truly a risk of lymphoma from biologic therapies? DermatolTher 2009; 22: 418-430.
15. Ferrandiz C, Carrascosa JM, Boada A. A new era in the management of psoriasis? The biologics: facts and controversies. Clin Dermatol 2010; 28: 81-87.
16. Smolen JS, Weinblatt ME. When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step? AnnRheumDis 2008; 67: 1497-1498.
17. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
18. Iannone F, Trotta F, Montecucco C, et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 2007; 66: 249-252.
19. Nuijten MJ, Engelfriet P, Duijn K, Bruijn G, Wierz D, Koopmanschap M. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 2001; 19: 1051-1064.
20. Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther 2012; 29: 234-248.
21. Omidi Y. Translational researches require effective protocols for knowledge and technology transfer and integration. BioImpacts 2011; 1: 71-73.
22. Smith G. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228: 1315-1317.
23. Thie H, Meyer T, Schirrmann T, Hust M, Dubel S. Phage display derived therapeutic antibodies. CurrPharmBiotechnol 2008; 9: 439-446.
24. Dias-Neto E, Nunes DN, Giordano RJ, et al. Next-generation phage display: integrating and comparing available molecular tools to enable cost-effective high-throughput analysis. PLoS One 2009; 4: e8338.
25. Tohidkia MR, Barar J, Asadi F, Omidi Y. Molecular considerations for development of phage antibody libraries. J Drug Target 2012; 20: 195-208.
26. Lee CM, Iorno N, Sierro F, Christ D. Selection of human antibody fragments by phage display. Nat Protoc 2007; 2: 3001-3008.
27. Ignatovich O, Tomlinson IM, Popov AV, Bruggemann M, Winter G. Dominance of intrinsic genetic factors in shaping the human immunoglobulin V-lambda repertoire. J Mol Biol 1999; 294: 457-465.
28. Bothmann H, Pluckthun A. Selection for a periplasmic factor improving phage display and functional periplasmic expression. Nat Biotech 1998; 16: 376-80.
29. Gunnarsen K, Lunde E, Kristiansen P, Bogen B, Sandlie I, Loset G. Periplasmic expression of soluble single chain T cell receptors is rescued by the chaperone FkpA 1099. BMC Biotechnology 2010; 10: 8.
30. Laemmli UK. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4. Nature 1970; 227: 680-685.
31. Guevara J, Johnston DA, Ramagali LS, Martin BA, Capetillo S, Rodriguez LV. Quantitative aspects of silver deposition in proteins resolved in complex polyacrylamide gels. Electrophoresis 1982; 3: 197-205.
32. Mostafaie A, Abdolalizadeh J. Immunogens of Brucella abortus (S19) identified by two-dimensional gel electrophoresis and immunobloting. Iran J Med Sci 2005; 30: 10-15.
33. Baradaran B, Majidi J, Hassan Z, Abdolalizadeh J. Large scale production and characterization of anti-human IgG monoclonal antibody in peritoneum of Balb/c mice. Am J Biochem Biotechnol 2006; 1: 190-193.
34. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979; 76: 4350-4354.
35. Belibasakis G, Johansson A, Wang Y, et al. Cytokine responses of human gingival fibroblasts to Actinobacillus actinomycetemcomitans cytolethal distending toxin. Cytokine 2005; 30: 56-63.
36. Botero JE, Contreras A, Parra B. Profiling of inflammatory cytokines produced by gingival fibroblasts after human cytomegalovirus infection. Oral Microbiol Immunol 2008; 23: 291-298.
37. Diya Z, Lili C, Shenglai L, Zhiyuan G, Jie Y. Lipopolysaccharide (LPS) of Porphyromonas gingivalis induces IL-1beta, TNF-alpha and IL-6 production by THP-1 cells in a way different from that of Escherichia coli LPS. Innate Immun 2008; 14: 99-107.
38. He X, Shu J, Xu L, Lu C, Lu A. Inhibitory Effect of Astragalus Polysaccharides on Lipopolysaccharide-Induced TNF-a and IL-1β Production in THP-1 Cells. Molecules 2012; 17: 3155-3164.
39. Peng T, Shen E, Fan J, Zhang Y, Arnold JM, Feng Q. Disruption of phospholipase Cgamma1 signalling attenuates cardiac tumor necrosis factor-alpha expression and improves myocardial function during endotoxemia. Cardiovasc Res 2008; 78: 90-97.
40. Chou YC, Sheu JR, Chung CL, Hsiao CJ, Hsueh PJ, Hsiao G. Hypertonicity-enhanced TNF-alpha release from activated human monocytic THP-1 cells requires ERK activation. Biochim Biophys Acta 2011; 1810: 475-484.
41. Abdolalizadeh J, Nouri M, Zolbanin JM, Baradaran B, Barzegari A, Omidi Y. Downstream characterization of anti-TNF-alpha single chain variable fragment antibodies. Hum Antibodies 2012; 21: 41-48.
42. Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Hum Antibodies 2009; 18: 81-100.
43. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480: 480-489.
44. Coukos G, Conejo-Garcia JR, Roden RB, Wu TC. Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther 2005; 5: 1193-1210.
45. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 1681-1690.
46. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? AnnuRev Immunol 2001; 19: 163-196.
47. Feldmann M, Maini RN. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature medicine 2003; 9: 1245-1250.
48. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006; 25: 409-416.
49. Maisey N. Antitumor necrosis factor (TNF-a) antibodies in the treatment of renal cell cancer. Cancer Invest 2007; 25: 589-593.
50. Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotech 2009; 27: 331-337.
51. Joosten V, Lokman C, Van Den Hondel CA, Punt PJ. The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. Microb Cell Fact 2003; 2: 1.
52. Le Gall F, Bove JM, Garnier M. Engineering of a single-chain variable-fragment (scFv) antibody specific for the stolbur phytoplasma (Mollicute) and its expression in escherichia coli and tobacco plants. Appl Environ Microbiol 1998; 64: 4566-4572.
53. Pilkington GR, Duan L, Zhu M, Keil W, Pomerantz RJ. Recombinant human Fab antibody fragments to HIV-1 Rev and Tat regulatory proteins: direct selection from a combinatorial phage display library. Mol Immunol 1996; 33: 439-450.
54. Tohidkia M, Asadi F, Barar J, Omidi Y. Selection of Potential Therapeutic Human Single-Chain Fv Antibodies against Cholecystokinin-B/Gastrin Receptor by Phage Display Technology. BioDrugs 2013; 27: 55-67.
55. Arnold FH. Metal-Affinity Separations: A New Dimension in Protein Processing. Nat Biotech 1991; 9: 151-156.
56. Jiang Y, Li F, Zha D, et al. Purification process development of a recombinant monoclonal antibody expressed in glycoengineered Pichia pastoris. Protein Expr Purif 2011; 76: 7-14.
57. Mohammadi M, Rasaee MJ, Rajabibazl M, Paknejad M, Zare M, Mohammadzadeh S. Epitope mapping of PR81 anti-MUC1 monoclonal antibody following PEPSCAN and phage display techniques. Hybridoma (Larchmt) 2007; 26: 223-230.
58. Lopez-Cepero M, Garcia-Sanz JA, Herbert L, et al. Soluble and membrane-bound TNF-alpha are involved in the cytotoxic activity of B cells from tumor-bearing mice against tumor targets. J Immunol 1994; 152: 3333-3341.
59. Haney D, Quigley MF, Asher TE, et al. Isolation of viable antigenspecific CD8+ T cells based on membrane-bound tumor necrosis factor (TNF)-alpha expression. J Immunol Methods 2011; 369: 33-41.
60. Milenic DE. Monoclonal antibody-based therapy strategies: providing options for the cancer patient. Curr Pharm Des 2002; 8: 1749-1764.